[1] Kmush B, Wierzba T, Krain L, et al. Epidemiology of hepatitis E in low- and middle-income countries of Asia and Africa. Semin Liver Dis, 2013, 33: 15-29.
[2] Rein DB, Stevens GA, Theaker J, et al. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology, 2012, 55: 988-997.
[3] Riezebos-Brilman A, Verschuuren EA, van Son WJ, et al. The clinical course of hepatitis E virus infection in patients of a tertiary Dutch hospital over a 5-year period. J Clin Virol, 2013, 58: 509-514.
[4] Pfefferle S, Frickmann H, Gabriel M, et al. Fatal course of an autochthonous hepatitis E virus infection in a patient with leukemia in Germany. Infection, 2012, 40: 451-454.
[5] Jagjit Singh GK, Ijaz S, Rockwood N, et al. Chronic Hepatitis E as a cause for cryptogenic cirrhosis in HIV. J Infect, 2013, 66: 103-106.
[6] Gisa A, Suneetha PV, Behrendt P, et al. Cross-genotype-specific T-cell responses in acute hepatitis E virus (HEV) infection. J Viral Hepat, 2016, 23: 305-315.
[7] Husain MM, Aggarwal R, Kumar D, et al. Effector T cells immune reactivity among patients with acute hepatitis E. J Viral Hepat, 2011, 18: e603-e608.
[8] Wang X, Li M, Li S, et al. Prophylaxis against hepatitis E: at risk populations and human vaccines. Expert Rev Vaccines, 2016, 15: 815-827.
[9] Gu G, Huang H, Zhang L, et al. Hepatitis E virus seroprevalence in pregnant women in Jiangsu, China, and postpartum evolution during six years. BMC Infect Dis, 2015, 15: 560.
[10] Kamar N, Abravanel F, Selves J, et al. Influence of immunosupp-ressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation. Transplantation, 2010, 89: 353-360.
[11] Tripathy AS, Das R, Rathod SB, et al. Cytokine profiles, CTL response and T cell frequencies in the peripheral blood of acute patients and individuals recovered from hepatitis E infection. PLoS One, 2012, 7: e31822.
[12] Mateos-Lindemann ML, Diez-Aguilar M, Galdamez AL, et al. Patients infected with HIV are at high-risk for hepatitis E virus infection in Spain. J Med Virol, 2014, 86: 71-74.
[13] Fujiwara S, Yokokawa Y, Morino K, et al. Chronic hepatitis E: a review of the literature. J Viral Hepat, 2014, 21: 78-89.
[14] Schlosser B, Stein A, Neuhaus R, et al. Liver transplant from a donor with occult HEV infection induced chronic hepatitis and cirrhosis in the recipient. J Hepatol, 2012, 56: 500-502.
[15] Kamar N, Rostaing L, Abravanel F, et al. Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation. Clin Infect Dis, 2010, 50: e30-e33.
[16] Haagsma EB, Riezebos-Brilman A, van den Berg AP, et al. Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b. Liver Transpl, 2010, 16: 474-477.
[17] Todt D, Francois C, Anggakusuma, et al. Antiviral Activity of Different Interferon Types and Subtypes Against Hepatitis E Virus Replication. Antimicrob Agents Chemother, 2016, 60: 2132-2139.
[18] Lhomme S, Kamar N, Nicot F, et al. Mutation in the Hepatitis E Virus Polymerase and Outcome of Ribavirin Therapy. Antimicrob Agents Chemother, 2015, 60: 1608-1614.
[19] Rivero-Juarez A, Martinez-Duenas L, Martinez-Peinado A, et al. High hepatitis E virus seroprevalence with absence of chronic infection in HIV-infected patients. J Infect, 2015, 70: 624-630.
[20] Riveiro-Barciela M, Buti M, Homs M, et al. Cirrhosis, liver transplantation and HIV infection are risk factors associated with hepatitis E virus infection. PLoS One, 2014, 9: e103028. |
